Our Take
A podcast recap of conference highlights is useful reporting only if it names specific drugs, trial outcomes, or patient populations—this one doesn't, making it a serviceable but hollow summary.
Why it matters
ASCO 2026 moved the needle on combination therapies and next-gen modalities like ADCs and bispecific antibodies. Oncology practitioners need to know which readouts actually shifted clinical practice, not just which ones generated buzz.
Do this week
Oncology strategists: listen to the full podcast episode before your next pipeline review so you can map which ASCO 2026 readouts affect your trial design or commercial timelines.
Two analysts break down ASCO 2026's top moments
GlobalData senior oncology analysts Jack Cuthbertson and Selena Yu attended the 2026 American Society of Clinical Oncology conference and shared their conference takeaways in a podcast with Clinical Trials Arena. The pair highlighted clinical readouts spanning hematological malignancies (multiple myeloma) and solid tumors (non-small cell lung cancer, pancreatic cancer). Both named their "wow moment" readouts and discussed whether high-anticipated presentations met expectations.
Across the five-day event, next-generation modalities dominated the agenda. Antibody-drug conjugates (ADCs), cancer vaccines, in vivo cell and gene therapies (CGTs), and bispecific antibodies were featured prominently as the field shifts toward combination targeted therapy plus chemotherapy regimens.
The oncology pipeline is maturing toward complexity
ASCO 2026 reflected a structural shift in how cancer treatments are being designed and sequenced. Single-agent approaches are giving way to rational combinations, and the drugs enabling that shift are increasingly sophisticated biologics. ADCs and bispecific antibodies reduce off-target toxicity; cancer vaccines and cell therapies add precision to immunotherapy.
For trial sponsors, payers, and clinical teams, the readouts from ASCO matter because they signal which drug classes are advancing to late-stage trials and which combinations are entering standard-of-care discussions. The conference floor itself generates real-time market signals before official publications.
What practitioners should do now
Oncology teams and biotech strategists should listen to the full podcast to surface the specific drugs and trial designs that moved analyst expectations. The summary identifies disease areas and modality trends, but the full episode (available on Spotify via GlobalData Healthcare) names individual readouts, which is the actionable level for pipeline planning and commercial positioning.
Note: the source material does not detail which specific readouts the analysts highlighted as their top three moments, so practitioners will need to access the podcast directly to extract concrete trial data, enrollment numbers, efficacy signals, or regulatory flags tied to individual programs.